Collectively, our findings indicate that B-Myb regulates a common set of target genes and cell type-specific genes through collaboration with other transcription factors (e.g. NFY and MuvB complex) and binding to cell type-invariant promoters and cell type-specific enhancers and super-enhancers, and subsequently activates oncogenic pathways such as PI3K-AKT and promotes malignant progression in cancers. This evidence concerns the gene MYBL2 and cancer.